Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Adagrasib High Drug Load vs Reference Tablets
NCT06801418Phase 1Completed
- Sponsor
- Mirati Therapeutics
- Start
- Feb 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of adagrasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Mirati Therapeutics. Primary endpoints: Area Under the Plasma Concentration-time Curve from Time Zero Extrapolated to Infinite Time, Area Under the Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration and 1 more. Started Feb 2025; status: completed.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06801418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06801418.